XML 39 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Other Operating Income And Expenses
 6 Months Ended
Jun. 30, 2023
Analysis of income and expense [abstract]  
Other Operating Income and Expenses
B.15. OTHER OPERATING INCOME AND EXPENSES
Other operating income amounted to €617 million in the first half of 2023 (versus €416 million in the first half of 2022), and Other operating expenses to €1,422 million (versus € 1,204 million in the first half of 2022).
The main items included in Other operating income were: in the first half of 2023, (i) income from pharmaceutical partners of €160 million (versus €153 million in the first half of 2022), of which €102 million came from Regeneron (versus €133 million in the first half of 2022, see table below) and (ii) gains on disposals of assets and operations of €413 million, primarily on divestments of non strategic products (versus €288 million in the first half of 2022).
Other operating expenses for the first half of 2023 included €1,423 million of expenses related to Regeneron (versus €1,201 million in the first half of 2022), as shown in the table below.
(€ million)June 30, 2023 (6 months)June 30, 2022 (6 months)
December 31,
2022
(12 months)
Income & expense related to profit/loss sharing under the Monoclonal Antibody Alliance(1,449)(979)(2,325)
Additional share of profit paid by Regeneron towards development costs291 97 434 
Reimbursement to Regeneron of selling expenses incurred(260)(216)(476)
Total: Monoclonal Antibody Alliance(1,418)(1,098)(2,367)
Immuno-Oncology Alliance— 36 16 
Other (mainly Zaltrap® and Libtayo®)
97 (6)1,120 
Other operating income/(expenses), net related to Regeneron (1,321)(1,068)(1,231)
of which amount presented in “Other operating income” 102 133 1,147